======= PCGF2 ======= == Gene Information == * **Official Symbol**: PCGF2 * **Official Name**: polycomb group ring finger 2 * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=7703|7703]] * **UniProt**: [[https://www.uniprot.org/uniprot/P35227|P35227]] * **Interactions**: [[https://thebiogrid.org/search.php?search=PCGF2&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20PCGF2|Open PubMed]] * **OMIM**: [[https://omim.org/entry/600346|Open OMIM]] == Function Summary == * **Entrez Summary**: N/A * **UniProt Summary**: Transcriptional repressor. Binds specifically to the DNA sequence 5'-GACTNGACT-3'. Has tumor suppressor activity. May play a role in control of cell proliferation and/or neural cell development. Regulates proliferation of early T progenitor cells by maintaining expression of HES1. Also plays a role in antero- posterior specification of the axial skeleton and negative regulation of the self-renewal activity of hematopoietic stem cells (By similarity). Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility (PubMed:26151332). Within the PRC1-like complex, regulates RNF2 ubiquitin ligase activity (PubMed:26151332). {ECO:0000250|UniProtKB:P23798, ECO:0000269|PubMed:26151332}. |zf-C3HC4| |sex chromatin| |histone H2A-K119 monoubiquitination| |PRC1 complex| |histone H2A monoubiquitination| |histone H2A ubiquitination| |PcG protein complex| |histone monoubiquitination| |negative regulation of G0 to G1 transition| |histone ubiquitination| |regulation of G0 to G1 transition| |promoter-specific chromatin binding| |chromatin organization involved in negative regulation of transcription| |chromatin silencing| |protein monoubiquitination| |chromatin organization involved in regulation of transcription| |cellular response to hydrogen peroxide| |negative regulation of gene expression, epigenetic| |embryonic skeletal system morphogenesis| |histone acetylation| |cellular response to antibiotic| |response to hydrogen peroxide| |internal peptidyl-lysine acetylation| |peptidyl-lysine acetylation| |internal protein amino acid acetylation| |embryonic skeletal system development| |cellular response to reactive oxygen species| |protein acetylation| |gene silencing| |protein acylation| |response to reactive oxygen species| |cellular response to toxic substance| |anterior/posterior pattern specification| |negative regulation of apoptotic signaling pathway| |regulation of gene expression, epigenetic| |nuclear chromatin| |skeletal system morphogenesis| |cellular response to oxidative stress| |nuclear body| |embryonic organ morphogenesis| |response to antibiotic| |peptidyl-lysine modification| |negative regulation of cell cycle process| |regionalization| |histone modification| |covalent chromatin modification| |in utero embryonic development| |response to oxidative stress| |regulation of apoptotic signaling pathway| |cellular response to drug| |embryonic organ development| |pattern specification process| |skeletal system development| |response to toxic substance| |response to inorganic substance| |embryonic morphogenesis| |negative regulation of cell cycle| |chordate embryonic development| |embryo development ending in birth or egg hatching| |DNA-binding transcription factor activity| |protein ubiquitination| |chromatin organization| |regulation of cell cycle process| |protein modification by small protein conjugation| |negative regulation of transcription by RNA polymerase II| |peptidyl-amino acid modification| |negative regulation of apoptotic process| |negative regulation of programmed cell death| |animal organ morphogenesis| |embryo development| |protein modification by small protein conjugation or removal| |negative regulation of cell death| |response to drug| |cellular response to oxygen-containing compound| |chromosome organization| |regulation of cell cycle| |negative regulation of transcription, DNA-templated| |negative regulation of nucleic acid-templated transcription| |negative regulation of RNA biosynthetic process| |negative regulation of signal transduction| |negative regulation of RNA metabolic process| |negative regulation of cell communication| |negative regulation of signaling| |negative regulation of cellular macromolecule biosynthetic process| |negative regulation of nucleobase-containing compound metabolic process| |DNA binding| |negative regulation of macromolecule biosynthetic process| |negative regulation of cellular biosynthetic process| |regulation of apoptotic process| |negative regulation of biosynthetic process| |response to oxygen-containing compound| |regulation of programmed cell death| |negative regulation of response to stimulus| |regulation of cell death| |cellular response to stress| |negative regulation of gene expression| \\ === CRISPR Data === No hits were found. No correlation found to any other genes in chemogenomics. Global Fraction of Cell Lines Where Essential: 2/726 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|0/28| |bone|0/25| |breast|0/33| |central nervous system|0/56| |cervix|0/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|0/15| |kidney|0/21| |liver|0/20| |lung|0/75| |lymphocyte|0/14| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|1/16| |plasma cell|0/15| |prostate|0/1| |skin|0/24| |soft tissue|0/7| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/29| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 14000 * **Expression level (log2 read counts)**: 2.87 {{:chemogenomics:nalm6 dist.png?nolink |}}